DRMA: Nilai perusahaan marang bathi resik Dermata

Lambang korporat lan logo Dermata (DRMA)

Dermata Therapeutics (DRMA) price action reflects a current PE multiple of -0.30, with the company's revenues expected to be driven by the market launch of innovative treatments for rosacea and acne. The use of unique extended-release formulations enables the company to maintain significant pricing power. However, a narrow development profile and dependence on final clinical trials create substantial risks to business sustainability.

Rasio rega marang bathi Dermata Therapeutics (DRMA): kanggo periode 04.07.2022 - 13.11.2026

Rincian analitis perusahaan Dermata Therapeutics

- rega lan prakiraan konsensus rega:
Rega saham dermatarx.com|DRMA - Target konsensus
- informasi kapitalisasi pasar:
Nilai pasar Dermata Therapeutics, Inc.|DRMA - Nilai Total Perusahaan
- indikator nilai aset resik miturut neraca:
Aset Bersih saben Saham Dermata Therapeutics|DRMA - Nilai Buku Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku dermatarx.com|DRMA - Total Aset Perusahaan
- data liabilitas lan likuiditas perusahaan:
Koefisien Total Utang marang Modal Dermata Therapeutics|DRMA - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal Dermata Corp|DRMA - Gunggung utang perusahaan|Rasio utang marang nilai buku Dermata Therapeutics, Inc.|DRMA - Utang jangka dawa perusahaan|Utang jangka cendhak Dermata Therapeutics|Rasio jangkoan perantara dermatarx.com
- rincian bathi lan kelipatan pasar:
DRMA - Bathi resik perusahaan|Bathi mangsa ngarep Dermata Therapeutics|DRMA - Pangali P/E|Pangali Forward P/E Dermata Therapeutics Inc|DRMA - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Dermata Therapeutics, Inc.|DRMA - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Dermata Therapeutics|DRMA - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan dermatarx.com|DRMA - Wutah bathi resik saben saham ing taun iki|Proyeksi tambahing bathi saben saham ing taun ngarep Dermata Therapeutics
Ringkesan analisis perusahaan:dermatarx.com DRMA
Produk asil prodhuksi dermatarx.com

The P/E ratio reflects the proportion between the market value of a business and its annual net income. This metric measures the investment payback period through the lens of current earnings. By analyzing P/E fluctuations for Dermata Therapeutics (DRMA) on the GURU.Markets platform, an investor can see how the price depends on the binary risks of clinical trials. A narrow specialization in acne medications makes the multiple extremely volatile. High pipeline uncertainty turns this indicator into a marker of speculative expectations.

Pesaing wigati

Pangali P/E krystalbio.com|Koefisien rega marang bathi APGE (Apogee Therapeutics, Inc.)|ARQT (Arcutis) - Nilai perusahaan marang bathi resik|Rasio rega marang bathi Vericel Corp. VCEL|Periode bali modal bisnis Oruka Pharma (ORKA)|SMTI - Rasio rega marang bathi|DBVT - Pangali P/E|SLSN: Pangali P/E|DERM - Periode bali modal bisnis|Rasio rega marang bathi Forte Biosciences, Inc|Pangali rega marang bathi EMPG (Empro Corporation)|Pangali P/E SLGL|reviveprocare.com - Pangali rega marang bathi|Pangali P/E MDCX (Medicus Pharma)|Verrica Pharmaceuticals Inc (VRCA) - Kapitalisasi marang bathi|HOTH - Rasio rega marang bathi|Nilai perusahaan marang bathi resik BFRI (Biofrontera Inc.)|vynetherapeutics.com (VYNE) - Rasio rega marang bathi|Koefisien rega marang bathi Sonoma Pharmaceuticals, Inc.|QNRX (Quoin Pharmaceuticals Ltd) - Pangali P/E|Pangali P/E Azitra Inc|Koefisien rega marang bathi ELAB (Elevai Skincare)|Rasio rega pasar marang bathi resik RVNC